
    
      This study will consist of 2 parts. In Part 1, pexidartinib 800 mg/day (400 mg twice a day
      [BID]) will be administered on an empty stomach and tolerability and PK of pexidartinib will
      be evaluated to determine the initiation of Part 2. In Part 2, pexidartinib 800 mg/day (400
      mg BID) will be administered on an empty stomach and efficacy, safety, and PK of pexidartinib
      will be evaluated.
    
  